Regeneron Pharmaceuticals Inc (REGN)
Fixed asset turnover
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (ttm) | US$ in thousands | 13,044,200 | 13,025,200 | 12,601,200 | 12,306,100 | 12,113,500 | 13,654,100 | 14,171,800 | 16,451,800 | 16,014,400 | 13,499,700 | 12,328,800 | 9,147,000 | 8,455,000 | 8,201,600 | 7,974,500 | 7,957,900 | 7,839,900 | 7,598,200 | 7,213,600 | 6,889,000 |
Property, plant and equipment | US$ in thousands | 3,540,700 | 4,006,100 | 3,922,600 | 3,880,900 | 3,142,700 | 3,704,200 | 3,637,700 | 3,556,400 | 3,482,200 | 3,395,700 | 3,358,500 | 3,262,600 | 3,221,600 | 3,138,300 | 3,031,400 | 2,944,600 | 2,890,400 | 2,771,400 | 2,676,600 | 2,612,800 |
Fixed asset turnover | 3.68 | 3.25 | 3.21 | 3.17 | 3.85 | 3.69 | 3.90 | 4.63 | 4.60 | 3.98 | 3.67 | 2.80 | 2.62 | 2.61 | 2.63 | 2.70 | 2.71 | 2.74 | 2.70 | 2.64 |
December 31, 2023 calculation
Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $13,044,200K ÷ $3,540,700K
= 3.68
Regeneron Pharmaceuticals, Inc.'s fixed asset turnover has exhibited some fluctuations over the past eight quarters. The ratio peaked at 4.64 in Q1 2022 and has since shown a general declining trend, reaching a low of 3.16 in Q4 2023.
A fixed asset turnover ratio measures a company's ability to generate revenue from its fixed assets. A higher ratio indicates that the company is more efficient in utilizing its fixed assets to generate sales.
The recent decrease in Regeneron's fixed asset turnover may indicate a decrease in the company's efficiency in utilizing its fixed assets to generate revenue. It is essential for the company to analyze the reasons behind this trend and take necessary steps to improve asset utilization efficiency in the future.
Overall, while there have been fluctuations in Regeneron Pharmaceuticals, Inc.'s fixed asset turnover ratio, the company should focus on optimizing the usage of its fixed assets to enhance operational efficiency and profitability.
Peer comparison
Dec 31, 2023
See also:
Regeneron Pharmaceuticals Inc Net Fixed Asset Turnover (Quarterly Data)